Comment nous préparer à l'arrivée des biosimilaires de l'insuline ?

Insulin and analogs, issued from biotechnology, should be affected by the production of biosmilars. These drugs diverge from generic medications because they could exhibit some subtle differences (due to formulation and manufacturing processes) with the original references. The availability of such medications raises some concerns about extrapolation, traceability and interchangeability in comparison to the original products. The National Agencies and the diabetologists' community should prepare themselves for safely usage of insulin biosimilars since they are a substantial source of savings for both hospitals and Health care systems.